In a report published Wednesday, SunTrust Robinson Humphrey analyst John T. Boris reiterated a Buy rating and $95 price target on Eli Lilly and Co (NYSE: LLY). The analyst estimates that the U.S. biologics psoriasis market would grow at a CAGR of almost 11 percent to $8.5 billion by 2020, from $5.2 billion in 2015.

Globally, there are estimated to be 125 million patients suffering from psoriasis, with 7.5 million in the U.S. alone. Of these, about 20-30 percent are classified with moderate to severe psoriasis.

"We forecast the market share spilt between anti-TNFs & alternative biologics at ~52/48 percent by 2020E," Humphrey said.

Data from three pivotal psoriasis studies for Ixekizumab show that the drug's efficacy is superior to biologics and placebo. Given that the BLA for the drug was submitted for approval in the US and EU in 1H15, the analyst expects U.S. approval in early 2016, while expecting the company to file an sBLA in psoriatic arthritis in 2017.

Given the high remission rates and response consistency on maintenance of Ixekizumab, the analyst expects strong uptake for the drug, compared to existing competitors. "LLY indicated that it is in the process of building out a small sales force to support the global launch of IXE to a "small community" of targeted specialists," the SunTrust report stated.

The sales estimate for 2020 has been raised from $1.1 billion to $1.3 billion.

Latest Ratings for LLY

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

See more from Benzinga

• Eli Lilly Price Target Hiked To At Argus; Here's Why

© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.